$ Value
$98K
Shares
1,407
Price
$70
Filed
Jul 16
Insider
Name
Stamoulis Christiana
Title
EVP & Chief Financial Officer
CIK
0001502917
Roles
Transaction Details
Transaction Date
2025-07-14
Code
F
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
116,097
Footnotes
Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. | Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. | Including the July 15, 2025 grant, this includes an aggregate of 64,006 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. | Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. | The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Filing Info
Stamoulis Christiana's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-07 | HOLX | D | — |
| 2026-04-07 | HOLX | D | — |
| 2026-04-07 | HOLX | D | — |
| 2026-04-07 | HOLX | D | — |
| 2026-04-07 | HOLX | D | — |
| 2026-04-07 | HOLX | D | — |
| 2026-04-07 | HOLX | D | — |
| 2026-04-07 | HOLX | D | — |
| 2026-04-07 | HOLX | D | — |
| 2026-04-07 | HOLX | D | — |
Other Insiders at INCY (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| HARRIGAN EDMUND | — | — | 2026-03-31 |
|
CAGNONI PABLO J
President, Global Head of R&D
|
— | $1.8M | 2026-04-17 |
| BAKER BROS. ADVISORS LP | — | — | 2026-03-31 |
| Clancy Paul J | — | — | 2026-03-31 |
|
Meury William
Chief Executive Officer
|
— | — | 2026-04-15 |
|
Stein Steven H
CMO & Head of Late-Stage Dev.
|
— | — | 2026-04-15 |
|
Trotta Matteo
EVP, GM, Dermatology US
|
— | — | 2026-03-25 |